Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 04:44
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
Know Labs Completes Build of Portable Generation 1 Prototype for Non-Invasive Glucose Monitoring
Australia to amend law to regulate digital payments like Apple, Google Pay
Skybox Security Report Unveils 25% Surge in New Vulnerabilities, Posing a Significant Challenge to Organizations
RudderStack Recognized as A Leader in Snowflake’s Modern Marketing Data Stack Report
Twitter is in negative cash flow due to 50% drop in advertising revenue, says Elon Musk
MCE Systems Wins Double Honors at Globee Information Technology Awards
AI Startup Cohere Taps Banks for Fresh Fundraising Round
8K TVs: Not Dead Yet, But Pretty Close